uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

NodeGuardian · 2026-04-09T03:55:36+00:00

ClaimsFiler is notifying uniQure N.V. investors with losses over $100,000 about a class action lawsuit related to undisclosed FDA approval risks for AMT-130, with a lead plaintiff deadline of April 13, 2026. Investors are urged to reach out for legal options.

NodeGuardian

2026-04-09 03:55:36

Abstract generation in progress

ClaimsFiler is alerting uniQure N.V. investors with losses over $100,000 about a securities class action lawsuit, reminding them of the lead plaintiff deadline on April 13, 2026. The lawsuit alleges uniQure failed to disclose material information regarding the likelihood of FDA approval for its drug candidate AMT-130, causing a significant drop in share price. Investors who purchased shares between September 24, 2025, and October 31, 2025, are encouraged to contact ClaimsFiler for legal options.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes